Outlook Therapeutics Inc (OTLK) Price Prediction & ForecastOTLKOutlook Therapeutics Inc

Alphio's OTLK stock price prediction model matches the current Outlook Therapeutics Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $0.65 (+0.12%). The 1-week path is $0.65 (+1.02%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

Outlook Therapeutics Inc (OTLK) is not a strong buy right now due to its current price of $0.6449 and a low RSI of 32.554, indicating oversold conditions. The company has recently received FDA approval for its drug LYTENAVA, which could potentially generate over $500 million in annual sales by 2030, but it also reported a significant net loss of $20.3 million for Q3 2026. The stock has a forward P/E of 2.8498, suggesting potential undervaluation, but the high volatility and negative sentiment surrounding the stock create considerable risk.

Outlook Therapeutics Inc (OTLK) last closed at $0.6449, gaining +0.59%. These facts feed the 1-day and 1-week OTLK price prediction above.